KYV-101
Sponsors
Kyverna Therapeutics Inc., Charite Universitaetsmedizin Berlin KöR, David Porter, Kyverna Therapeutics, Stanford University
Conditions
ANCA Associated VasculitisANCA-IgG-positive ANCA associated vasculitisDermatomyositisDiffuse Cutaneous Systemic SclerosisGeneralized Myasthenia GravisIdiopathic Inflammatory MyopathiesLupus NephritisMS
Phase 1
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
Active, not recruitingNCT06152172
Start: 2024-08-05End: 2027-02-01Target: 24Updated: 2026-02-18
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
RecruitingNCT06298019
Start: 2024-08-02End: 2039-04-30Target: 21Updated: 2025-05-21
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Active, not recruitingNCT06400303
Start: 2024-08-06End: 2027-03-31Updated: 2025-10-08
COMparison of B-cell dePletion by rituximAb and anti-CD 19 CAR-T therapy in patients with rhEumatoid arthritis- The COMPARE TRIAL
TWO - STAGE INTERVENTIONAL, PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN LABEL, PARALLEL - GROUP PHASE I/II TRIAL IN PATIENTS WITH ACTIVE, ACPA – POSITIVE AND TREATMENT REFRACTORY RHEUMATOID ARTHRITIS
RecruitingCTIS2024-514955-13-00
Start: 2024-11-29Target: 16Updated: 2026-01-13
Anti-CD 19 CAR-T cell therapy in patients with ANCA Vasculitis: A two-stage interventional, prospective, open-label, phase I/II trial in patients with active, treatment refractory, ANCA-IgG-positive vasculitis
Not yet recruitingCTIS2024-517303-36-00
Target: 8Updated: 2024-12-09
Phase 2
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RecruitingNCT06193889
Start: 2024-08-28End: 2028-09-01Target: 66Updated: 2026-01-30
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Active, not recruitingNCT06384976
Start: 2024-09-20End: 2029-01-31Target: 120Updated: 2025-01-13
A Phase 2, Open-Label, Multicentre Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Generalized Myasthenia Gravis (KYSA-6)
RecruitingCTIS2023-509892-17-00
Start: 2024-07-09Target: 10Updated: 2025-08-07
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
Not yet recruitingCTIS2024-511168-10-00
Target: 88Updated: 2024-10-07
A Long-Term Follow-Up Protocol for Participants Previously Treated with KYV-101 (KYSA-4)
Not yet recruitingCTIS2024-511198-31-00
Target: 30Updated: 2026-03-06